Pox viridae treatment
AssigneeThe University of British Columbia
InventorsWilfred Arthur Jefferies, Timothy Z. Vitalis, Quian-Jin Zhang, Judi Barbara Alimonti, Susan Shu-Ping Chen, Genc Basha, Kyung Bok Choi
Life of this patent
Estimating the term…
Abstract
A vaccine composition for combating Pox viridae viral infections in living organisms such as mammals (including humans) comprises TAP-1 and/or TAP-2 to augment the antigen processing capability of infected cells and hence their immunogenicity. The composition may be used alone or, preferably, as an immunogenicity-enhancing adjuvant with a pox antigen-based vaccine, especially in the treatment or prophylaxis of viral infections such as smallpox.
Claims18
A pharmaceutical composition for administration to a living organism for the treatment or prophylaxis of Pox viridae infections, the composition comprising, for simultaneous or sequential administration:
- a Pox viridae viral vaccine containing live or attenuated Pox viridae virus, and
- an adjuvant comprising a pharmaceutically acceptable composition containing TAP-I and/or TAP-2, or precursors thereof.
Dependencies are inferred from the claim text.